Repurposed Treatment · 10 min read · Updated March 2026

Mebendazole: The $5 FDA-Approved Drug With Cancer Trial Data

A human dewormer with Phase I/II clinical trial data in glioblastoma and colorectal cancer. It crosses the blood-brain barrier, costs almost nothing, and has decades of safety data.

🔬 Grade B: Promising

The Bottom Line

Mebendazole (MBZ) is an FDA-approved antiparasitic drug that has emerged as one of the most credible repurposed cancer candidates. It has actual human clinical trial data (not just lab studies), crosses the blood-brain barrier (critical for brain tumors), costs $5-15 per course, and has decades of safety data from treating parasitic infections. If you're interested in benzimidazole drugs for cancer, this is the one with a rational evidence base, not fenbendazole.

What It Is

Mebendazole is a benzimidazole anthelmintic, FDA-approved for treating pinworms, hookworms, and other parasitic infections. It's generic, cheap, and available worldwide. The anticancer interest comes from its mechanism: it disrupts the same cellular structures (microtubules) that several chemotherapy drugs target.

How It Works Against Cancer

  • Microtubule disruption: Inhibits tubulin polymerization, the same mechanism as vincristine and paclitaxel (established chemo drugs). Cancer cells dividing rapidly are most vulnerable.
  • Hedgehog pathway inhibition: Blocks a signaling pathway aberrantly activated in many cancers (especially brain, prostate, pancreatic, basal cell carcinoma)
  • Apoptosis induction: Downregulates Bcl-2 (anti-death protein in cancer cells)
  • Anti-angiogenic: Inhibits VEGF, cutting off blood supply to tumors
  • Cell cycle arrest: Stops cancer cells at G2/M phase
  • HIF disruption: Disrupts HIF-1/HIF-2 in breast cancer cells (PMC9954103)
  • Crosses the blood-brain barrier: This is a critical advantage for brain tumors, where most drugs cannot reach

Human Clinical Trial Data

Colorectal Cancer RCT (2022)

A randomized controlled trial of 40 patients with metastatic colorectal cancer. Patients received bevacizumab/FOLFOX4 + mebendazole 500mg twice daily vs. placebo. Published in Life Sciences. This is real human RCT data for a repurposed drug.

Glioblastoma Phase I (NCT01729260)

24 patients (18 glioblastoma, 6 anaplastic gliomas) received mebendazole + temozolomide. Oral MBZ was safe at high doses. Results support safety and tolerability. The blood-brain barrier penetration makes this especially relevant for brain tumors, which are notoriously difficult to treat.

ReDO Project Review

The Repurposing Drugs in Oncology (ReDO) project, published in ecancer.org, concluded mebendazole is an "ideal candidate for repurposing" based on known pharmacokinetics, low toxicity, low cost, and strong preclinical evidence across multiple cancer types.

Preclinical Breadth

MBZ has shown activity against glioma, colorectal, breast, lung, adrenocortical, prostate, AML, head and neck, and ovarian cancers in laboratory models. This breadth of activity is consistent with its microtubule mechanism, since all rapidly dividing cells depend on microtubules.

Protocol (From Clinical Trials)

  • Dose: 500mg twice daily (1000mg/day), the dose used in human trials
  • Administration: Take with fatty food. Absorption drops dramatically without fat.
  • Duration: In trials, given continuously alongside standard treatments
  • Lower preventive dose: Some protocols use 100mg twice daily, 2-3 days per week

Safety Profile

Mebendazole has decades of safety data from treating hundreds of millions of people for parasitic infections. At cancer-relevant doses:

  • Generally well-tolerated
  • Elevated liver enzymes possible at high doses (monitor liver function tests)
  • Bone marrow suppression at very high doses (rare)
  • Abdominal discomfort and diarrhea
  • Drug interaction: cimetidine increases MBZ levels (CYP450 metabolism)

Mebendazole vs. Fenbendazole

Fenbendazole (the "Joe Tippens protocol" dog dewormer) gets more attention online due to a viral cancer remission story. But mebendazole is the smarter choice:

  • MBZ is FDA-approved for humans; fenbendazole is a veterinary drug with no human pharmacokinetic data
  • MBZ has Phase I/II clinical trial data; fenbendazole has zero human clinical trials
  • MBZ has well-characterized safety; fenbendazole has reports of liver toxicity in self-administering patients
  • MBZ crosses the blood-brain barrier; fenbendazole BBB penetration is not established
  • Both are benzimidazoles with the same core mechanism. MBZ is the evidence-based version.

Where to Get It

Mebendazole requires a prescription in most countries. It's available as a generic and costs $5-15 per course. Any physician can prescribe it off-label. Discussing the clinical trial data may help the conversation.

Our Assessment

Mebendazole is the real deal among benzimidazole drugs being explored for cancer. FDA-approved, human trial data, BBB penetration, multi-mechanism, nearly free. It's not proven as a standalone cancer treatment, but as an adjunct to standard therapy, the risk-benefit ratio is hard to argue against. Multiple ongoing trials will provide more data in the coming years.

Sources

  • PMC6769799: "Mebendazole as a Candidate for Drug Repurposing in Oncology" (comprehensive review)
  • PMC9862092: "Emerging Perspectives on MBZ as Repurposed Drug for Brain Cancers" (2023)
  • ScienceDirect S0024320522002363: RCT in metastatic colorectal cancer (2022)
  • PMC9954103: HIF disruption in breast cancer (2023)
  • ecancer.org/443: ReDO Project review
  • ClinicalTrials.gov NCT01729260: Phase I in glioblastoma

Medical Disclaimer: This is a research review, not medical advice. Always consult with qualified healthcare professionals before making any changes to your health regimen.

How we grade evidence: Grade A = Phase II+ RCT with positive signal. Grade B = Phase I/II or strong epidemiology. Grade C = Preclinical only. Debunked = Retracted or disproven. Full methodology →